Русский
Rehabilitation of patients after modern endourological procedures for urolithiasis
DOI: https://dx.doi.org/10.18565/urology.2018.4.49-55
A.G. Martov, D.V. Ergakov
D.D. Pletnev City Clinical Hospital, Moscow Health Department (Head Physician – Ph.D., I.A. Nazarova), Department of Urology #2; Department of Urology and Andrology (Head – Dr.Med.Sci., Prof. A.G. Martov), A.I. Burnazyan SSC Federal Medical Biophysical Center of FMBA of Russia, Moscow, Russia
Introduction. Numerous publications on the successful use of NefraDoz® (Stada, Germany) in the metaphylaxis of urolithiasis after extracorporeal lithotripsy, and the prevention and treatment of infectious inflammatory diseases of the lower and upper urinary tracts, served as the rationale for a study aimed to evaluate the effectiveness and safety of long-term use of NefraDoz® in patients after transurethral and percutaneous interventions performed for urological diseases.
Patients and methods. The study analyzed results of 116 transurethral and percutaneous endoscopic operations for urolithiasis performed in 62 men and 54 women aged 21 to 84 years from November to December 2017 at the D.D. Pletnev City Clinical Hospital. Depending on the localization of the stones, all patients were divided into three groups: kidney stones (n=68), ureteral stones (n=28), and bladder stones (n=21). In each group, patients were assigned either to receive (study group, n=50) or not to receive (control group, n=66) postoperative NefraDoz®, which was administered at a dose of 1 capsule three times daily for one month. Patients in the control group (n=66) received standard antibacterial therapy for one month. The analysis included leukocyturia, 24-hour diuresis, the severity of the symptoms of the disease and the patients’ quality of life.
Results. The use of NefraDoz® after transurethral lower urinary tract procedures, reduced the severity of irritative symptoms, improved the patients’ quality of life, reduced the number of patients with leukocyturia and increased 24-hour diuresis. The use of NefraDoz® after upper urinary tract procedures improved the patients’ quality of life, reduced the number of patients with leukocyturia and increased 24-hour diuresis, and improved the clearance of residual fragments. There were no adverse events associated with NefraDoz®.
Conclusions. We have proved the advantage of using the NefraDoz® complex in the rehabilitation of patients after endourologic procedures.
Patients and methods. The study analyzed results of 116 transurethral and percutaneous endoscopic operations for urolithiasis performed in 62 men and 54 women aged 21 to 84 years from November to December 2017 at the D.D. Pletnev City Clinical Hospital. Depending on the localization of the stones, all patients were divided into three groups: kidney stones (n=68), ureteral stones (n=28), and bladder stones (n=21). In each group, patients were assigned either to receive (study group, n=50) or not to receive (control group, n=66) postoperative NefraDoz®, which was administered at a dose of 1 capsule three times daily for one month. Patients in the control group (n=66) received standard antibacterial therapy for one month. The analysis included leukocyturia, 24-hour diuresis, the severity of the symptoms of the disease and the patients’ quality of life.
Results. The use of NefraDoz® after transurethral lower urinary tract procedures, reduced the severity of irritative symptoms, improved the patients’ quality of life, reduced the number of patients with leukocyturia and increased 24-hour diuresis. The use of NefraDoz® after upper urinary tract procedures improved the patients’ quality of life, reduced the number of patients with leukocyturia and increased 24-hour diuresis, and improved the clearance of residual fragments. There were no adverse events associated with NefraDoz®.
Conclusions. We have proved the advantage of using the NefraDoz® complex in the rehabilitation of patients after endourologic procedures.
About the Autors
Corresponding author: D.V. Ergakov – Ph.D., Urologist at the Department of Urology, D.D. Pletnev CCH; Associate Professor at Department of Urology and Andrology, IPPE of A.I. Burnazyan SSC FMBC, FMBA of Russia, Moscow, Russia; e-mail: dergakov@mail.ru
Similar Articles
